The PGS pass rate for blastocysts is usually 60-70%. PGS, or preimplantation genetic screening, is a method of early prenatal screening prior to implantation in the body for implantation, in which researchers test early embryos for chromosome number and structural abnormalities, and analyze the embryos for abnormal genetic material by testing the structure and number of the 23 pairs of chromosomes in a single visit, so that normal embryos can be selected for implantation in the uterus in anticipation of a normal pregnancy, increasing the patient’s clinical pregnancy rate and reducing multiple pregnancies. If both sexes have no chromosomal abnormalities, the pass rate is nearly 100%, but this is the absolute ideal. At the same time, PGS cannot cover all diseases because PGS sampling is limited to a small number of cleavage globules or blastocyst stage cells. This does not affect the normal development of the embryo, but the genetic makeup of the cells taken and the cell mass left to continue development are not identical, so there can be discrepancies in screening results for certain chromosomal chimeric disorders. In addition, the cause of chromosomal disorders is still unknown, and PGS cannot completely prevent embryonic abnormalities. Even if a healthy embryo is selected, chromosomal abnormalities can occur in the fetus during the early stages of development after embryo transfer due to maternal and environmental factors. Therefore, after successful conception by PGS, pregnant women still need to undergo routine prenatal checkups, and PGS is not a substitute for prenatal screening. If fetal abnormalities are found during routine prenatal checkups, or if the pregnant woman has indications for prenatal screening, she is advised to choose prenatal screening methods such as amniocentesis for confirmation.